Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DA-005
- Development stage
- Phase 3
- Lead developer
- Derm-All Matrix
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Topical
01
Overview
DA-005 is an experimental topical biologic treatment developed by the South Korean company Derm-All Matrix for the treatment of androgenetic alopecia (hair loss). The drug utilizes the company's proprietary extracellular matrix (ECM) technology, which involves solubilized ECM components designed to regenerate the hair follicle environment. By providing structural support and signaling molecules, DA-005 aims to stimulate hair follicle activity and promote hair regrowth. It has been evaluated in clinical trials, including a Phase 1/2 study (NCT04848311), where its safety and efficacy were assessed alongside other formulations such as DA-002.
- Other names
- DA-005DA005DA 005
Beyond the preview
Go deeper on DA-005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DA-005.